Search

Your search keyword '"Klotz, L."' showing total 1,529 results
Start Over Author "Klotz, L."
1,529 results on '"Klotz, L."'

117. 3:45 PM Abstract No. 341 Pivotal study of magnetic resonance imaging–guided transurethral ultrasound ablation in men with localized prostate cancer: 12-month clinical and imaging outcomes

Author

Raman, S., primary, Futterer, J., additional, Oto, A., additional, Arora, S., additional, Tirkes, T., additional, Macura, K., additional, Bonekamp, D., additional, Haider, M., additional, Cool, D., additional, Nandalur, K., additional, Nicolau, C., additional, Costa, D., additional, Persigehl, T., additional, Purysko, A., additional, Staruch, R., additional, Burtnyk, M., additional, Chin, J., additional, Klotz, L., additional, and Eggener, S., additional

Published
2020
Full Text
View/download PDF

119. Corrigendum to 'European contribution to the study of ROS:A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)' [Redox Biol. 13 (2017) 94-162]

Author

Egea, J., Fabregat, I., Frapart, Y. M., Ghezzi, P., Görlach, A., Kietzmann, T., Kubaichuk, K., Knaus, U. G., Lopez, M. G., Olaso-Gonzalez, G., Petry, A., Schulz, R., Vina, J., Winyard, P., Abbas, K., Ademowo, O. S., Afonso, C. B., Andreadou, I., Antelmann, H., Antunes, F., Aslan, M., Bachschmid, M. M., Barbosa, R. M., Belousov, V., Berndt, C., Bernlohr, D., Bertrán, E., Bindoli, A., Bottari, S. P., Brito, P. M., Carrara, G., Casas, A. I., Chatzi, A., Chondrogianni, N., Conrad, M., Cooke, M. S., Costa, J. G., Cuadrado, A., My-Chan Dang, P., De Smet, B., Debelec-Butuner, B., Dias, I. H.K., Dunn, J. D., Edson, A. J., El Assar, M., El-Benna, J., Ferdinandy, P., Fernandes, A. S., Fladmark, K. E., Förstermann, U., Giniatullin, R., Giricz, Z., Görbe, A., Griffiths, H., Hampl, V., Hanf, A., Herget, J., Hernansanz-Agustín, P., Hillion, M., Huang, J., Ilikay, S., Jansen-Dürr, P., Jaquet, V., Joles, J. A., Kalyanaraman, B., Kaminskyy, D., Karbaschi, M., Kleanthous, M., Klotz, L. O., Korac, B., Korkmaz, K. S., Koziel, R., Kračun, D., Krause, K. H., Křen, V., Krieg, T., Laranjinha, J., Lazou, A., Li, H., Martínez-Ruiz, A., Matsui, R., McBean, G. J., Meredith, S. P., Messens, J., Miguel, V., Mikhed, Y., Milisav, I., Milković, L., Miranda-Vizuete, A., Mojović, M., Monsalve, M., Mouthuy, P. A., Mulvey, J., Münzel, T., Muzykantov, V., Nguyen, I. T.N., Oelze, M., Oliveira, N. G., Palmeira, C. M., Papaevgeniou, N., Pavićević, A., Pedre, B., Peyrot, F., Phylactides, M., Pircalabioru, G. G., Pitt, A. R., Poulsen, H. E., Prieto, I., Rigobello, M. P., Robledinos-Antón, N., Rodríguez-Mañas, L., Rolo, A. P., Rousset, F., Ruskovska, T., Saraiva, N., Sasson, S., Schröder, K., Semen, K., Seredenina, T., Shakirzyanova, A., Smith, G. L., Soldati, T., Sousa, B. C., Spickett, C. M., Stancic, A., Stasia, M. J., Steinbrenner, H., Stepanić, V., Steven, S., Tokatlidis, K., Tuncay, E., Turan, B., Ursini, F., Vacek, J., Vajnerova, O., Valentová, K., Van Breusegem, F., Varisli, L., Veal, E. A., Yalçin, A. S., Yelisyeyeva, O., Žarković, N., Zatloukalová, M., Zielonka, J., Touyz, R. M., Papapetropoulos, A., Grune, T., Lamas, S., Schmidt, H. H.H.W., Di Lisa, F., and Daiber, A.

Published
2018

120. Comparison of micro-ultrasound and multiparametric MRI imaging for prostate cancer: A multicentre prospective analysis

Author

Lughezzani, G., primary, Pereira, J.G., additional, Sánchez, A., additional, Staerman, F., additional, Cash, H., additional, Lopez, L., additional, Rouffilange, J., additional, Gaston, R., additional, Klein, E., additional, Abouassaly, R., additional, El-Shefai, A., additional, Klotz, L., additional, and Eure, G., additional

Published
2019
Full Text
View/download PDF

121. Reply by Authors

Author

Salari, K., primary, Kuppermann, D., additional, Preston, M. A., additional, Dahl, D. M., additional, Barrisford, G. W., additional, Efstathiou, J. A., additional, Blute, M. L., additional, Vesprini, D., additional, Loblaw, A., additional, Zietman, A. L., additional, Klotz, L., additional, and Feldman, A. S., additional

Published
2019
Full Text
View/download PDF

131. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project

Author

Luijtelaar, A. van, Greenwood, B.M., Ahmed, H.U., Barqawi, A.B., Barret, E., Bomers, J.G.R., Brausi, Maurizio, Choyke, P.L., Cooperberg, M.R., Eggener, S., Feller, J.F., Frauscher, F., George, A.K., Hindley, R.G., Jenniskens, S.F.M., Klotz, L., Kovacs, G., Lindner, U., Loeb, S., Margolis, D.J., Marks, L.S., May, S., McClure, T.D., Montironi, R., Nour, S.G., Oto, A., Polascik, T.J., Rastinehad, A.R., Reyke, T.M. De, Reijnen, J.S., Rosette, J. de la, Sedelaar, J.P.M., Sperling, D.S., Walser, E.M., Ward, J.F., Villers, A., Ghai, S., Futterer, J.J., Luijtelaar, A. van, Greenwood, B.M., Ahmed, H.U., Barqawi, A.B., Barret, E., Bomers, J.G.R., Brausi, Maurizio, Choyke, P.L., Cooperberg, M.R., Eggener, S., Feller, J.F., Frauscher, F., George, A.K., Hindley, R.G., Jenniskens, S.F.M., Klotz, L., Kovacs, G., Lindner, U., Loeb, S., Margolis, D.J., Marks, L.S., May, S., McClure, T.D., Montironi, R., Nour, S.G., Oto, A., Polascik, T.J., Rastinehad, A.R., Reyke, T.M. De, Reijnen, J.S., Rosette, J. de la, Sedelaar, J.P.M., Sperling, D.S., Walser, E.M., Ward, J.F., Villers, A., Ghai, S., and Futterer, J.J.

Abstract

Contains fulltext : 208360.pdf (publisher's version ) (Open Access), PURPOSE: To define the role of focal laser ablation (FLA) as clinical treatment of prostate cancer (PCa) using the Delphi consensus method. METHODS: A panel of international experts in the field of focal therapy (FT) in PCa conducted a collaborative consensus project using the Delphi method. Experts were invited to online questionnaires focusing on patient selection and treatment of PCa with FLA during four subsequent rounds. After each round, outcomes were displayed, and questionnaires were modified based on the comments provided by panelists. Results were finalized and discussed during face-to-face meetings. RESULTS: Thirty-seven experts agreed to participate, and consensus was achieved on 39/43 topics. Clinically significant PCa (csPCa) was defined as any volume Grade Group 2 [Gleason score (GS) 3+4]. Focal therapy was specified as treatment of all csPCa and can be considered primary treatment as an alternative to radical treatment in carefully selected patients. In patients with intermediate-risk PCa (GS 3+4) as well as patients with MRI-visible and biopsy-confirmed local recurrence, FLA is optimal for targeted ablation of a specific magnetic resonance imaging (MRI)-visible focus. However, FLA should not be applied to candidates for active surveillance and close follow-up is required. Suitability for FLA is based on tumor volume, location to vital structures, GS, MRI-visibility, and biopsy confirmation. CONCLUSION: Focal laser ablation is a promising technique for treatment of clinically localized PCa and should ideally be performed within approved clinical trials. So far, only few studies have reported on FLA and further validation with longer follow-up is mandatory before widespread clinical implementation is justified.

Published
2019

132. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.

Author

Rannikko A., Moore C.M., Gnanapragasam V., Van Hemelrijck M., Dasgupta P., Bangma C., Villers A., Valdagni R., Perry A., Hugosson J., Rubio-Briones J., Bjartell A., Hefermehl L., Shiong L.L., Frydenberg M., Kakehi Y., Chung B.H., Obbink H., van der Linden W., Hulsen T., de Jonge C., Kattan M., Xinge J., Muir K., Lophatananon A., Fahey M., Steyerberg E., Zhang L., Guo W., Benfante N., Cowan J., Patil D., Tolosa E., Kim T.-K., Mamedov A., Lapointe V., Crump T., Kimberly-Duffell J., Santaolalla A., Olivier J., Rancati T., Ahlgren H., Mascaros J., Lofgren A., Lehmann K., Lin C.H., Hirama H., Lee K.S., Jenster G., Auvinen A., Haider M., van Bochove K., Carter B., Gledhill S., Buzza M., van der Kwast T.H., Helleman J., Nieboer D., Bruinsma S.M., Roobol M.J., Trock B., Ehdaie B., Carroll P., Filson C., Kim J., Logothetis C., Morgan T., Klotz L., Pickles T., Hyndman E., Rannikko A., Moore C.M., Gnanapragasam V., Van Hemelrijck M., Dasgupta P., Bangma C., Villers A., Valdagni R., Perry A., Hugosson J., Rubio-Briones J., Bjartell A., Hefermehl L., Shiong L.L., Frydenberg M., Kakehi Y., Chung B.H., Obbink H., van der Linden W., Hulsen T., de Jonge C., Kattan M., Xinge J., Muir K., Lophatananon A., Fahey M., Steyerberg E., Zhang L., Guo W., Benfante N., Cowan J., Patil D., Tolosa E., Kim T.-K., Mamedov A., Lapointe V., Crump T., Kimberly-Duffell J., Santaolalla A., Olivier J., Rancati T., Ahlgren H., Mascaros J., Lofgren A., Lehmann K., Lin C.H., Hirama H., Lee K.S., Jenster G., Auvinen A., Haider M., van Bochove K., Carter B., Gledhill S., Buzza M., van der Kwast T.H., Helleman J., Nieboer D., Bruinsma S.M., Roobol M.J., Trock B., Ehdaie B., Carroll P., Filson C., Kim J., Logothetis C., Morgan T., Klotz L., Pickles T., and Hyndman E.

Abstract

Within the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative, 25 centers across the globe collaborate to standardize active surveillance (AS) protocols for men with low-risk prostate cancer (PCa). A centralized PCa AS database, comprising data of more than 15 000 patients worldwide, was created. Comparability of the histopathology between the different cohorts was assessed by a centralized pathology review of 445 biopsies from 15 GAP3 centers. Grade group 1 (Gleason score 6) in 85% and grade group >=2 (Gleason score >=7) in 15% showed 89% concordance at review with moderate agreement (kappa = 0.56). Average biopsy core length was similar among the analyzed cohorts. Recently established highly adverse pathologies, including cribriform and/or intraductal carcinoma, were observed in 3.6% of the reviewed biopsies. In conclusion, the centralized pathology review of 445 biopsies revealed comparable histopathology among the 15 GAP3 centers with a low frequency of high-risk features. This enables further data analyses-without correction-toward uniform global AS guidelines for men with low-risk PCa. Patient Summary: Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative combines data from 15 000 men with low-risk prostate cancer (PCa) across the globe to standardize active surveillance protocols. Histopathology review confirmed that the histopathology was consistent with low-risk PCa in most men and comparable between different centers. A centralized pathological review showed consistent biopsy quality and Gleason grading within the global active surveillance Global Action Plan 3 initiative, a prerequisite for future studies toward uniform global guidelines for active surveillance of men with low-risk prostate cancer.Copyright © 2018

Published
2019

133. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Author

Perry A., Gledhill S., Morgan T., Klotz L., Pickles T., Hyndman E., Moore C.M., Dasgupta P., Villers A., Valdagni R., Carter B., Hugosson J., Rubio-Briones J., Bjartell A., Hefermehl L., Lui Shiong L., Kakehi Y., Ha Chung B., van der Kwast T., Obbink H., Hulsen T., de Jonge C., Xinge J., Muir K., Lophatananon A., Steyerberg E., Zhang L., Santa Olalla A., Beckmann K., Denton B., Hayen A., Boutros P., Guo W., Benfante N., Cowan J., Patil D., Tolosa E., Kim T.-K., Mamedov A., La Pointe V., Crump T., Kimberly-Duffell J., Santaolalla A., Olivier J., Rancati T., Ahlgren H., Mascaros J., Lofgren A., Lehmann K., Han Lin C., Hirama H., Suk Lee K., Jenster G., Auvinen A., Haider M., van Bochove K., Buzza M., Bangma C., Bruinsma S., Fahey M., Van Hemelrijck M., Ji X., Kattan M.W., Helleman J., Roobol M.J., Nieboer D., Bangma C.H., van der Linden W., Frydenberg M., Rannikko A., Lee L.S., Gnanapragasam V.J., Trock B., Ehdaie B., Carroll P., Filson C., Kim J., Logothetis C., Perry A., Gledhill S., Morgan T., Klotz L., Pickles T., Hyndman E., Moore C.M., Dasgupta P., Villers A., Valdagni R., Carter B., Hugosson J., Rubio-Briones J., Bjartell A., Hefermehl L., Lui Shiong L., Kakehi Y., Ha Chung B., van der Kwast T., Obbink H., Hulsen T., de Jonge C., Xinge J., Muir K., Lophatananon A., Steyerberg E., Zhang L., Santa Olalla A., Beckmann K., Denton B., Hayen A., Boutros P., Guo W., Benfante N., Cowan J., Patil D., Tolosa E., Kim T.-K., Mamedov A., La Pointe V., Crump T., Kimberly-Duffell J., Santaolalla A., Olivier J., Rancati T., Ahlgren H., Mascaros J., Lofgren A., Lehmann K., Han Lin C., Hirama H., Suk Lee K., Jenster G., Auvinen A., Haider M., van Bochove K., Buzza M., Bangma C., Bruinsma S., Fahey M., Van Hemelrijck M., Ji X., Kattan M.W., Helleman J., Roobol M.J., Nieboer D., Bangma C.H., van der Linden W., Frydenberg M., Rannikko A., Lee L.S., Gnanapragasam V.J., Trock B., Ehdaie B., Carroll P., Filson C., Kim J., and Logothetis C.

Abstract

Background: Careful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa). Objective(s): Using Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation. Design, setting, and participants: We compared data from 10 296 men on AS from 21 centres across 12 countries. Outcome measurements and statistical analysis: Cumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation. Results and limitations: During 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5 yr, 4561 had follow-up for <5 yr, and 149 were lost to follow-up. Cumulative incidence of progression was 27.5% (95% CI: 26.4-28.6%) at 5 yr and 38.2% (95% CI: 36.7-39.9%) at 10 yr. A limitation is that not all centres were included due to limited information on the reason for discontinuation and limited follow-up. Conclusion(s): Our descriptive analyses of current AS practices worldwide showed that 43.6% of men drop out of AS during 5-yr follow-up, mainly due to signs of disease progression. Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to AS, which will also reduce discontinuation due to conversion to active treatment without evidence of disease progression. Patient Summary: Our assessment of a worldwide database of men with prostate cancer (PCa) on active surveillance (AS) shows that 43.6% drop out of AS within 5 yr, mainly due to signs of disease progression. Better tools are needed to select and monitor men with PCa as part of AS. After about 5 yr, about 56% of men were still

Published
2019

134. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.

Author

Santaolalla A., Gnanapragasam V., Van Hemelrijck M., Dasgupta P., Auvinen A., Haider M., van Bochove K., Carter B., Gledhill S., Buzza M., Bruinsma S., Helleman J., Drost F.-J.H., Nieboer D., Morgan T.M., Carroll P.R., Roobol M.J., Trock B., Ehdaie B., Carroll P., Filson C., Kim J., Logothetis C., Morgan T., Klotz L., Pickles T., Hyndman E., Bangma C., Roobol M., Villers A., Rannikko A., Valdagni R., Perry A., Hugosson J., Rubio-Briones J., Bjartell A., Hefermehl L., Shiong L.L., Frydenberg M., Kakehi Y., Chung B.H., van der Kwast T., van der Linden W., Hulsen T., de Jonge C., Kattan M., Xinge J., Muir K., Lophatananon A., Fahey M., Steyerberg E., Zhang L., Beckmann K., Denton B., Hayen A., Boutros P., Guo W., Benfante N., Cowan J., Patil D., Tolosa E., Kim T.-K., Mamedov A., Lapointe V., Crump T., Kimberly-Duffell J., Olivier J., Rancati T., Ahlgren H., Mascaros J., Lofgren A., Lin C.H., Hirama H., Lee K.S., Moore C.M., Jenster G., Santaolalla A., Gnanapragasam V., Van Hemelrijck M., Dasgupta P., Auvinen A., Haider M., van Bochove K., Carter B., Gledhill S., Buzza M., Bruinsma S., Helleman J., Drost F.-J.H., Nieboer D., Morgan T.M., Carroll P.R., Roobol M.J., Trock B., Ehdaie B., Carroll P., Filson C., Kim J., Logothetis C., Morgan T., Klotz L., Pickles T., Hyndman E., Bangma C., Roobol M., Villers A., Rannikko A., Valdagni R., Perry A., Hugosson J., Rubio-Briones J., Bjartell A., Hefermehl L., Shiong L.L., Frydenberg M., Kakehi Y., Chung B.H., van der Kwast T., van der Linden W., Hulsen T., de Jonge C., Kattan M., Xinge J., Muir K., Lophatananon A., Fahey M., Steyerberg E., Zhang L., Beckmann K., Denton B., Hayen A., Boutros P., Guo W., Benfante N., Cowan J., Patil D., Tolosa E., Kim T.-K., Mamedov A., Lapointe V., Crump T., Kimberly-Duffell J., Olivier J., Rancati T., Ahlgren H., Mascaros J., Lofgren A., Lin C.H., Hirama H., Lee K.S., Moore C.M., and Jenster G.

Abstract

Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings. Background: Men with prostate cancer (PCa) on active surveillance (AS) are followed through regular prostate biopsies, a burdensome and often unnecessary intervention, not without risks. Identifying men with at a low risk of disease reclassification may help reduce the number of biopsies. Objective(s): To assess the external validity of two Canary Prostate Active Surveillance Study Risk Calculators (PASS-RCs), which estimate the probability of reclassification (Gleason grade >=7 with or without >34% of biopsy cores positive for PCa) on a surveillance biopsy, using a mix of months since last biopsy, age, body mass index, prostate-specific antigen, prostate volume, number of prior negative biopsies, and percentage (or ratio) of positive cores on last biopsy. Design, setting, and participants: We used data up to November 2017 from the Movember Foundation's Global Action Plan (GAP3) consortium, a global collaboration between AS studies. Outcome measurements and statistical analysis: External validity of the PASS-RCs for estimating reclassification on biopsy was assessed by calibration, discrimination, and decision curve analyses. Results and limitations: Five validation cohorts (Prostate Cancer Research International: Active Surveillance, Johns Hopkins, Toronto, Memorial Sloan Kettering Cancer Center, and University of California San Francisco), comprising 5105 men on AS, were eligible for analysis. The individual cohorts comprised 429-2416 men, with a median follow-up between 36 and 84 mo, in both community and academic practices mainly from western countries. Abilities of the PASS-RCs to discriminate between men with and without reclassification on biopsy were reasonab

Published
2019

135. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

Author

Crawford, ED, Heidenreich, A, Lawrentschuk, N, Tombal, B, Pompeo, ACL, Mendoza-Valdes, A, Miller, K, Debruyne, FMJ, Klotz, L, Crawford, ED, Heidenreich, A, Lawrentschuk, N, Tombal, B, Pompeo, ACL, Mendoza-Valdes, A, Miller, K, Debruyne, FMJ, and Klotz, L

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies that suppress testosterone (T) levels or inactivate its function, improvements in diagnostic and assay technologies, identification of lower therapeutic targets for T, discovery of the relevance of germline genetic mutations and identification of the benefits of sequential and combination therapies. METHODS: This review discusses the clinical profiles of the most up-to-date options for ADT, best practices for managing patients with advanced PCa and future directions in therapy. RESULTS AND CONCLUSIONS: Modern assay technologies reveal that bilateral orchiectomy results in a serum T level of approximately 15 ng/dL as compared to the historical definition of castration of T < 50 ng/dL. Evidence shows that lowering T levels to <20 ng/dL improves patient survival and delays disease progression. Routine monitoring of T in addition to prostate-specific antigen throughout treatment is important to ensure continuing efficacy of T suppression. New drugs that inhibit androgen signaling in combination with traditional ADT suppress T activity to near zero and have significantly improved patient survival. When personalizing ADT regimens physicians should consider a number of factors including initiation and duration of ADT, monitoring of T levels and PSA, the possibility of switching monotherapies if a patient does not achieve adequate T suppression, and consideration of intermittent vs. continuous ADT according to patients' lifestyles, comorbidities, risk factors and tolerance to treatment.

Published
2019

136. Immunophenotyping of cerebrospinal fluid cells in ischaemic stroke

Author

Schulte‐Mecklenbeck, A., primary, Kleffner, I., additional, Beuker, C., additional, Wirth, T., additional, Hartwig, M., additional, Schmidt‐Pogoda, A., additional, Klotz, L., additional, Hansen, W., additional, Wiendl, H., additional, Meuth, S. G., additional, Gross, C. C., additional, and Minnerup, J., additional

Published
2019
Full Text
View/download PDF

139. Tumor-derived granulocyte chemotactic protein 2 cooperates with neutrophil proteinase 3 to drive lung adenocarcinoma

Author

Lamort, A, primary, Weiß, S, additional, Lillis, I, additional, Armenis, V, additional, Arendt, K, additional, Pepe, M, additional, Klotz, L, additional, Marazioti, A, additional, Spella, M, additional, Giopanou, I, additional, Ntaliarda, G, additional, Giotopoulou, G, additional, Lianou, M, additional, Oplopoiou, M, additional, Kauka, K, additional, Jenne, D, additional, and Stathopoulos, G, additional

Published
2018
Full Text
View/download PDF

144. Corrigendum to 'European contribution to the study of ROS : A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)' [Redox Biol. 13 (2017) 94-162]

Author

Egea, J, Fabregat, I, Frapart, Y M, Ghezzi, P, Görlach, A, Kietzmann, T, Kubaichuk, K, Knaus, U G, Lopez, M G, Olaso-Gonzalez, G, Petry, A, Schulz, R., Vina, J, Winyard, P.J., Abbas, K, Ademowo, O S, Afonso, C B, Andreadou, I, Antelmann, H, Antunes, F, Aslan, M, Bachschmid, M M, Barbosa, M.R.V., Belousov, V, Berndt, C, Bernlohr, D, Bertrán, E, Bindoli, A, Bottari, S P, Brito, P M, Carrara, G, Casas, A I, Chatzi, A, Chondrogianni, N, Conrad, M., Cooke, M S, Gil-da-Costa, Maria J, Cuadrado, A, My-Chan Dang, P, de Smet, M.B.M, Debelec-Butuner, B, Dias, I H K, Dunn, J D, Edson, A J, El Assar, M, El-Benna, J, Ferdinandy, Pter, Fernandes, A S, Fladmark, K E, Förstermann, U, Giniatullin, R, Giricz, Zoltán, Görbe, Anikó, Griffiths, Helen L, Hampl, V, Hanf, A, Herget, J, Hernansanz-Agustín, P, Hillion, M, Huang, J, Ilikay, S, Jansen-Dürr, P, Jaquet, V, Joles, J A, Kalyanaraman, B, Kaminskyy, D, Karbaschi, M, Kleanthous, M, Klotz, L O, Korac, B, Korkmaz, K. S., Koziel, R, Kračun, D, Krause, K H, Křen, V, Krieg, T., Laranjinha, J, Lazou, A, Li, H., Martínez-Ruiz, A, Matsui, R, McBean, G J, Meredith, S P, Messens, J, Miguel, V, Mikhed, Y, Milisav, I, Milković, L, Miranda-Vizuete, A, Mojović, M, Monsalve, M, Mouthuy, P A, Mulvey, J, Münzel, Thomas, Muzykantov, V, Nguyen, I T N, Oelze, M, Oliveira, Nelson Gomes, Palmeira, C M, Papaevgeniou, N, Pavićević, A, Pedre, B, Peyrot, F, Phylactides, M, Pircalabioru, G G, Pitt, A R, Poulsen, H E, Prieto, I, Rigobello, M P, Robledinos-Antón, N, Rodríguez-Mañas, L, Rolo, A P, Rousset, F, Ruskovska, T, Saraiva, N, Sasson, S, Schröder, K, Semen, K, Seredenina, T., Shakirzyanova, A, Smith, Godfrey L, Soldati, T, Sousa, B C, Spickett, C M, Stancic, A, Stasia, M.J., Steinbrenner, H, Stepanić, V, Steven, S, Tokatlidis, K, Tuncay, E, Turan, B, Ursini, F, Vacek, J, Vajnerova, O, Valentová, K, Van Breusegem, F, Varisli, L, Veal, E A, Yalçın, A S, Yelisyeyeva, O, Žarković, N, Zatloukalová, M, Zielonka, J, Touyz, R M, Papapetropoulos, A, Grune, T, Lamas, S, Schmidt, H H H W, Di Lisa, F, Daiber, A, Egea, J, Fabregat, I, Frapart, Y M, Ghezzi, P, Görlach, A, Kietzmann, T, Kubaichuk, K, Knaus, U G, Lopez, M G, Olaso-Gonzalez, G, Petry, A, Schulz, R., Vina, J, Winyard, P.J., Abbas, K, Ademowo, O S, Afonso, C B, Andreadou, I, Antelmann, H, Antunes, F, Aslan, M, Bachschmid, M M, Barbosa, M.R.V., Belousov, V, Berndt, C, Bernlohr, D, Bertrán, E, Bindoli, A, Bottari, S P, Brito, P M, Carrara, G, Casas, A I, Chatzi, A, Chondrogianni, N, Conrad, M., Cooke, M S, Gil-da-Costa, Maria J, Cuadrado, A, My-Chan Dang, P, de Smet, M.B.M, Debelec-Butuner, B, Dias, I H K, Dunn, J D, Edson, A J, El Assar, M, El-Benna, J, Ferdinandy, Pter, Fernandes, A S, Fladmark, K E, Förstermann, U, Giniatullin, R, Giricz, Zoltán, Görbe, Anikó, Griffiths, Helen L, Hampl, V, Hanf, A, Herget, J, Hernansanz-Agustín, P, Hillion, M, Huang, J, Ilikay, S, Jansen-Dürr, P, Jaquet, V, Joles, J A, Kalyanaraman, B, Kaminskyy, D, Karbaschi, M, Kleanthous, M, Klotz, L O, Korac, B, Korkmaz, K. S., Koziel, R, Kračun, D, Krause, K H, Křen, V, Krieg, T., Laranjinha, J, Lazou, A, Li, H., Martínez-Ruiz, A, Matsui, R, McBean, G J, Meredith, S P, Messens, J, Miguel, V, Mikhed, Y, Milisav, I, Milković, L, Miranda-Vizuete, A, Mojović, M, Monsalve, M, Mouthuy, P A, Mulvey, J, Münzel, Thomas, Muzykantov, V, Nguyen, I T N, Oelze, M, Oliveira, Nelson Gomes, Palmeira, C M, Papaevgeniou, N, Pavićević, A, Pedre, B, Peyrot, F, Phylactides, M, Pircalabioru, G G, Pitt, A R, Poulsen, H E, Prieto, I, Rigobello, M P, Robledinos-Antón, N, Rodríguez-Mañas, L, Rolo, A P, Rousset, F, Ruskovska, T, Saraiva, N, Sasson, S, Schröder, K, Semen, K, Seredenina, T., Shakirzyanova, A, Smith, Godfrey L, Soldati, T, Sousa, B C, Spickett, C M, Stancic, A, Stasia, M.J., Steinbrenner, H, Stepanić, V, Steven, S, Tokatlidis, K, Tuncay, E, Turan, B, Ursini, F, Vacek, J, Vajnerova, O, Valentová, K, Van Breusegem, F, Varisli, L, Veal, E A, Yalçın, A S, Yelisyeyeva, O, Žarković, N, Zatloukalová, M, Zielonka, J, Touyz, R M, Papapetropoulos, A, Grune, T, Lamas, S, Schmidt, H H H W, Di Lisa, F, and Daiber, A

Published
2018

145. The Movember Foundation's GAP3 cohort

Author

Bruinsma, S.M. (Sophie), Zhang, L. (Liying), Roobol-Bouts, M.J. (Monique), Bangma, C.H. (Chris), Steyerberg, E.W. (Ewout), Nieboer, D. (Daan), Van Hemelrijck, M. (Mieke), Trock, B.J. (Bruce), Ehdaie, B. (Behfar), Carroll, P.R. (Peter), Filson, C. (Christopher), Kim, J. (Jeri), Morgan, T. (Todd), Klotz, L. (Laurence), Pickles, T. (Tom), Hyndman, E. (Eric), Moore, C.M. (Caroline), Gnanapragasam, V. (Vincent), Dasgupta, P. (Prokar), Villers, A. (Arnoud), Rannikko, A.S. (Antti), Valdagni, R. (Riccardo), Perry, A. (Antoinette), Hugosson, J. (Jonas), Rubio-Briones, J. (Jose), Bjartell, A. (Anders), Hefermehl, L. (Lukas), Lui Shiong, L. (Lee), Frydenberg, M. (Mark), Kakehi, Y. (Yoshiyuki), Ha Chung, B. (Byung), Kwast, Th.H. (Theo) van der, Obbink, H. (Henk), van der Linden, W. (Wim), Hulsen, T. (Tim), de Jonge, C. (Cees), Kattan, M.W. (Michael), Xinge, J. (Ji), Muir, K. (Kenneth), Lophatananon, A. (Artitaya), Fahey, M. (Michael), Guo, W. (Wei), Milan, T. (Tanya), Benfante, N. (Nicole), Cowan, J. (Janet), Patil, D. (Dattatraya), Sanford, R. (Rachel), Kim, T.-K. (Tae-Kyung), Mamedov, A. (Alexandre), LaPointe, V. (Vincent), Crump, T. (Trafford), Hamoudi, R. (Rifat), Kimberly-Duffell, J. (Jenna), Santaolalla, A. (Aida), Olivier, J. (Jonathan), Janetti, E.B. (Emanuele Bianchi), Rancati, T. (Tiziana), Ahlgren, H. (Helén), Mascarós, J. (Juanma), Löfgren, A. (Annica), Lehmann, K. (Kurt), Han Lin, C. (Catherine), Hirama, H. (Hiromi), Jenster, G.W. (Guido), Auvinen, A. (Anssi), Haider, M. (Masoom), van Bochove, K. (Kees), Carter, B. (Ballentine), Kirk-Burnnand, R. (Rachelle), Gledhill, S. (Sam), Buzza, M. (Mark), Bruinsma, S.M. (Sophie), Zhang, L. (Liying), Roobol-Bouts, M.J. (Monique), Bangma, C.H. (Chris), Steyerberg, E.W. (Ewout), Nieboer, D. (Daan), Van Hemelrijck, M. (Mieke), Trock, B.J. (Bruce), Ehdaie, B. (Behfar), Carroll, P.R. (Peter), Filson, C. (Christopher), Kim, J. (Jeri), Morgan, T. (Todd), Klotz, L. (Laurence), Pickles, T. (Tom), Hyndman, E. (Eric), Moore, C.M. (Caroline), Gnanapragasam, V. (Vincent), Dasgupta, P. (Prokar), Villers, A. (Arnoud), Rannikko, A.S. (Antti), Valdagni, R. (Riccardo), Perry, A. (Antoinette), Hugosson, J. (Jonas), Rubio-Briones, J. (Jose), Bjartell, A. (Anders), Hefermehl, L. (Lukas), Lui Shiong, L. (Lee), Frydenberg, M. (Mark), Kakehi, Y. (Yoshiyuki), Ha Chung, B. (Byung), Kwast, Th.H. (Theo) van der, Obbink, H. (Henk), van der Linden, W. (Wim), Hulsen, T. (Tim), de Jonge, C. (Cees), Kattan, M.W. (Michael), Xinge, J. (Ji), Muir, K. (Kenneth), Lophatananon, A. (Artitaya), Fahey, M. (Michael), Guo, W. (Wei), Milan, T. (Tanya), Benfante, N. (Nicole), Cowan, J. (Janet), Patil, D. (Dattatraya), Sanford, R. (Rachel), Kim, T.-K. (Tae-Kyung), Mamedov, A. (Alexandre), LaPointe, V. (Vincent), Crump, T. (Trafford), Hamoudi, R. (Rifat), Kimberly-Duffell, J. (Jenna), Santaolalla, A. (Aida), Olivier, J. (Jonathan), Janetti, E.B. (Emanuele Bianchi), Rancati, T. (Tiziana), Ahlgren, H. (Helén), Mascarós, J. (Juanma), Löfgren, A. (Annica), Lehmann, K. (Kurt), Han Lin, C. (Catherine), Hirama, H. (Hiromi), Jenster, G.W. (Guido), Auvinen, A. (Anssi), Haider, M. (Masoom), van Bochove, K. (Kees), Carter, B. (Ballentine), Kirk-Burnnand, R. (Rachelle), Gledhill, S. (Sam), and Buzza, M. (Mark)

Abstract

Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate-specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.

Published
2018
Full Text
View/download PDF

146. Absence of Epstein-Barr virus seronegativity in a large cohort of patients with early multiple sclerosis

Author

Abrahamyan, S., Eberspaecher, B., Ambrosius, B., Hessler, N., Antony, G., Koenig, I. R., Hoshi, M. -M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Bergh, F. Then, Tumani, H., Kuempfel, T., Stangel, M., Heesen, C., Wildemann, B., Paul, F., Bayas, A., Warnke, C., Weber, F., Linker, R. A., Ziemann, U., Zettl, U. K., Zipp, F., Wiendl, H., Hemmer, B., Gold, R., Salmen, A., Ruprecht, K., Abrahamyan, S., Eberspaecher, B., Ambrosius, B., Hessler, N., Antony, G., Koenig, I. R., Hoshi, M. -M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Bergh, F. Then, Tumani, H., Kuempfel, T., Stangel, M., Heesen, C., Wildemann, B., Paul, F., Bayas, A., Warnke, C., Weber, F., Linker, R. A., Ziemann, U., Zettl, U. K., Zipp, F., Wiendl, H., Hemmer, B., Gold, R., Salmen, A., and Ruprecht, K.

Published
2018

147. Changes of disease characteristics and disease-modifying treatment within one year in the National German MS cohort

Author

Ambrosius, B., Hessler, N., Antony, G., Konig, I. R., Hoshi, M-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Bergh, F. Then, Tumani, H., Kuempfel, T., Stangel, M., Heesen, C., Wildemann, B., Paul, F., Bayas, A., Warnke, C., Weber, F., Linker, R. A., Ziemann, U., Zettl, U. K., Zipp, F., Wiendl, H., Hemmer, B., Gold, R., Salmen, A., Ambrosius, B., Hessler, N., Antony, G., Konig, I. R., Hoshi, M-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Tackenberg, B., Stoppe, M., Bergh, F. Then, Tumani, H., Kuempfel, T., Stangel, M., Heesen, C., Wildemann, B., Paul, F., Bayas, A., Warnke, C., Weber, F., Linker, R. A., Ziemann, U., Zettl, U. K., Zipp, F., Wiendl, H., Hemmer, B., Gold, R., and Salmen, A.

Published
2018

148. Corrigendum to 'European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)' [Redox Biol. 13 (2017) 94-162]

Author

CMM Groep Burgering, MS Nefrologie, Regenerative Medicine and Stem Cells, Circulatory Health, Nefro Vasculaire Geneeskunde, Other research (not in main researchprogram), Egea, J, Fabregat, I, Frapart, Y M, Ghezzi, P, Görlach, A, Kietzmann, T, Kubaichuk, K, Knaus, U G, Lopez, M G, Olaso-Gonzalez, G, Petry, A, Schulz, R., Vina, J, Winyard, P.J., Abbas, K, Ademowo, O S, Afonso, C B, Andreadou, I, Antelmann, H, Antunes, F, Aslan, M, Bachschmid, M M, Barbosa, M.R.V., Belousov, V, Berndt, C, Bernlohr, D, Bertrán, E, Bindoli, A, Bottari, S P, Brito, P M, Carrara, G, Casas, A I, Chatzi, A, Chondrogianni, N, Conrad, M., Cooke, M S, Gil-da-Costa, Maria J, Cuadrado, A, My-Chan Dang, P, de Smet, M.B.M, Debelec-Butuner, B, Dias, I H K, Dunn, J D, Edson, A J, El Assar, M, El-Benna, J, Ferdinandy, Pter, Fernandes, A S, Fladmark, K E, Förstermann, U, Giniatullin, R, Giricz, Zoltán, Görbe, Anikó, Griffiths, Helen L, Hampl, V, Hanf, A, Herget, J, Hernansanz-Agustín, P, Hillion, M, Huang, J, Ilikay, S, Jansen-Dürr, P, Jaquet, V, Joles, J A, Kalyanaraman, B, Kaminskyy, D, Karbaschi, M, Kleanthous, M, Klotz, L O, Korac, B, Korkmaz, K. S., Koziel, R, Kračun, D, Krause, K H, Křen, V, Krieg, T., Laranjinha, J, Lazou, A, Li, H., Martínez-Ruiz, A, Matsui, R, McBean, G J, Meredith, S P, Messens, J, Miguel, V, Mikhed, Y, Milisav, I, Milković, L, Miranda-Vizuete, A, Mojović, M, Monsalve, M, Mouthuy, P A, Mulvey, J, Münzel, Thomas, Muzykantov, V, Nguyen, I T N, Oelze, M, Oliveira, Nelson Gomes, Palmeira, C M, Papaevgeniou, N, Pavićević, A, Pedre, B, Peyrot, F, Phylactides, M, Pircalabioru, G G, Pitt, A R, Poulsen, H E, Prieto, I, Rigobello, M P, Robledinos-Antón, N, Rodríguez-Mañas, L, Rolo, A P, Rousset, F, Ruskovska, T, Saraiva, N, Sasson, S, Schröder, K, Semen, K, Seredenina, T., Shakirzyanova, A, Smith, Godfrey L, Soldati, T, Sousa, B C, Spickett, C M, Stancic, A, Stasia, M.J., Steinbrenner, H, Stepanić, V, Steven, S, Tokatlidis, K, Tuncay, E, Turan, B, Ursini, F, Vacek, J, Vajnerova, O, Valentová, K, Van Breusegem, F, Varisli, L, Veal, E A, Yalçın, A S, Yelisyeyeva, O, Žarković, N, Zatloukalová, M, Zielonka, J, Touyz, R M, Papapetropoulos, A, Grune, T, Lamas, S, Schmidt, H H H W, Di Lisa, F, Daiber, A, CMM Groep Burgering, MS Nefrologie, Regenerative Medicine and Stem Cells, Circulatory Health, Nefro Vasculaire Geneeskunde, Other research (not in main researchprogram), Egea, J, Fabregat, I, Frapart, Y M, Ghezzi, P, Görlach, A, Kietzmann, T, Kubaichuk, K, Knaus, U G, Lopez, M G, Olaso-Gonzalez, G, Petry, A, Schulz, R., Vina, J, Winyard, P.J., Abbas, K, Ademowo, O S, Afonso, C B, Andreadou, I, Antelmann, H, Antunes, F, Aslan, M, Bachschmid, M M, Barbosa, M.R.V., Belousov, V, Berndt, C, Bernlohr, D, Bertrán, E, Bindoli, A, Bottari, S P, Brito, P M, Carrara, G, Casas, A I, Chatzi, A, Chondrogianni, N, Conrad, M., Cooke, M S, Gil-da-Costa, Maria J, Cuadrado, A, My-Chan Dang, P, de Smet, M.B.M, Debelec-Butuner, B, Dias, I H K, Dunn, J D, Edson, A J, El Assar, M, El-Benna, J, Ferdinandy, Pter, Fernandes, A S, Fladmark, K E, Förstermann, U, Giniatullin, R, Giricz, Zoltán, Görbe, Anikó, Griffiths, Helen L, Hampl, V, Hanf, A, Herget, J, Hernansanz-Agustín, P, Hillion, M, Huang, J, Ilikay, S, Jansen-Dürr, P, Jaquet, V, Joles, J A, Kalyanaraman, B, Kaminskyy, D, Karbaschi, M, Kleanthous, M, Klotz, L O, Korac, B, Korkmaz, K. S., Koziel, R, Kračun, D, Krause, K H, Křen, V, Krieg, T., Laranjinha, J, Lazou, A, Li, H., Martínez-Ruiz, A, Matsui, R, McBean, G J, Meredith, S P, Messens, J, Miguel, V, Mikhed, Y, Milisav, I, Milković, L, Miranda-Vizuete, A, Mojović, M, Monsalve, M, Mouthuy, P A, Mulvey, J, Münzel, Thomas, Muzykantov, V, Nguyen, I T N, Oelze, M, Oliveira, Nelson Gomes, Palmeira, C M, Papaevgeniou, N, Pavićević, A, Pedre, B, Peyrot, F, Phylactides, M, Pircalabioru, G G, Pitt, A R, Poulsen, H E, Prieto, I, Rigobello, M P, Robledinos-Antón, N, Rodríguez-Mañas, L, Rolo, A P, Rousset, F, Ruskovska, T, Saraiva, N, Sasson, S, Schröder, K, Semen, K, Seredenina, T., Shakirzyanova, A, Smith, Godfrey L, Soldati, T, Sousa, B C, Spickett, C M, Stancic, A, Stasia, M.J., Steinbrenner, H, Stepanić, V, Steven, S, Tokatlidis, K, Tuncay, E, Turan, B, Ursini, F, Vacek, J, Vajnerova, O, Valentová, K, Van Breusegem, F, Varisli, L, Veal, E A, Yalçın, A S, Yelisyeyeva, O, Žarković, N, Zatloukalová, M, Zielonka, J, Touyz, R M, Papapetropoulos, A, Grune, T, Lamas, S, Schmidt, H H H W, Di Lisa, F, and Daiber, A

Published
2018

149. Diet and Hygiene Between Ethics and Medicine: Evidence and the Reception of Alvise Cornaro’s La Vita Sobria in Early Seventeenth-Century England

Author

Klotz, L, Baldassarri, F, Brissay, P, Connolly, P, Malesevic, F, Guariento, L, Filson, L, Segev, R, Knetsch, R, Bellini, F, Mori, J, Lancaster, JAT, Raiswell R, Bellini, Federico, federico bellini (ORCID:0000-0001-8434-0384), Klotz, L, Baldassarri, F, Brissay, P, Connolly, P, Malesevic, F, Guariento, L, Filson, L, Segev, R, Knetsch, R, Bellini, F, Mori, J, Lancaster, JAT, Raiswell R, Bellini, Federico, and federico bellini (ORCID:0000-0001-8434-0384)

Abstract

Alvise Cornaro’s Treatises on the Sober Life (Discorsi della vita sobria) was one of the most popular books on diet and hygiene across the whole of Europe from its publication in the sixteenth century up to the early twentieth century. In this chapter, I show that the reasons for the success of Cornaro’s work in early modern England lie in the fact that two very different communities of practice saw the work’s conclusions as grounded upon a particular configuration of evidence that resonated with them: one spiritual, where it was used as part of an attempt to forge a via media between Puritans and Anglicans; the other medical, where it served as a case study from which more general conclusions about how to prolong life might be extrapolated. The unique context in which the first English translation of the Discorsi was conceived, produced, and published—involving some of the most prominent intellectual figures of the time, such as Francis Bacon, Nicholas Ferrar, and George Herbert—make this an important case study, useful for the reconstruction of a significant chapter of the history of dieting and hygiene, and the history of conceptions of evidence and their relationship to different communities of practice.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results